Coronavirus company news summary – Health Canada authorises sale of Spartan Bioscience’s rapid Covid-19 test – P&G and Rhinostics partner to take innovative nasal swab to market

25 January 2021 (Last Updated January 25th, 2021 09:22)

Spartan Bioscience has been granted Health Canada approval to sell the Spartan Covid-19 System, a rapid, on-site molecular diagnostic test to detect the SARS-CoV-2 virus. The test is the first mobile, rapid PCR test for Covid-19 in the Canadian market.

Beckman Coulter, a clinical diagnostics company, has launched its Access SARS-CoV-2 IgG II assay in countries that accept the CE Mark certification. The new antibody test identifies the patient’s level of antibodies in response to a prior SARS-CoV-2 infection. This allows clinicians to assess an individual’s immune response to the virus over time.

P&G has partnered with Rhinostics to take its novel nasal swab to the clinical laboratory market. P&G developed the swab in an effort to support communities to bring innovative solutions and meet supply shortages at laboratories and supply chains during the pandemic.

The Foundation for Innovative New Diagnostics (FIND) and Unitaid, announced that the first contracts have been finalised on behalf of the Access to Covid-19 Tools (ACT) Accelerator Diagnostics Pillar, after an open call for Expressions of Interest (EOI) that was launched on July 2020. This is expected to drive equal access of over 250 million antigen rapid tests for Covid-19 across low- and middle-income countries for a price of $2.50.